Evidence of Amniotic Epithelial Cell Differentiation toward Hepatic Sinusoidal Endothelial Cells

Monica Serra¹*, Michela Marongiu¹*, Antonella Contini¹, Toshio Miki², Erika Cadoni¹, Ezio Laconi¹, and Fabio Marongiu¹

Abstract

Amniotic epithelial cells (AECs) represent a useful and noncontroversial source for liver-based regenerative medicine, as they can differentiate into hepatocytes upon transplantation into the liver. However, the possibility that AECs can differentiate into other liver cell types, such as hepatic sinusoidal endothelial cells (HSECs), has never been assessed. In order to test this hypothesis, rat- and human-derived AECs (rAECs and hAECs, respectively) were subjected to endothelial cell tube formation assay in vitro. Moreover, to evaluate differentiation in vivo, the retrorsine (RS) model of liver repopulation was used. Pyrrolizidine alkaloids (including RS) are known to target both hepatocytes and endothelial cells, inducing cell enlargement and inhibition of cell cycle progression. rAECs and hAECs were able to form capillary-like structures when cultured under proangiogenic conditions. For in vivo experiments, rAECs were obtained from dipeptidyl peptidase type IV (DPP-IV, CD26) donors and were transplanted into the liver of recipient CD26 negative animals pretreated with RS. rAEC-derived cells were engrafted in between hepatocytes and resembled HSECs as assessed by morphological analysis and the pattern of expression of CD26. Donor-derived CD26⁺ cells coexpressed HSEC markers RECA-1 and SE-1, while they lacked expression of typical hepatocyte markers (i.e., cytochrome P450, hepatocyte nuclear factor 4α). As such, these results provide the first evidence that AECs can respond to proangiogenic signals in vitro and differentiate into HSECs in vivo. Furthermore, they support the conclusion that AECs possesses great plasticity and represents a promising tool in the field of regenerative medicine both in the liver and in other organs.

Keywords

amniotic epithelial cells, hepatic sinusoidal endothelial cells, stem cell differentiation, cell transplantation

Introduction

Because of their stem cell characteristics, human-derived amniotic epithelial cells (hAECs) isolated from term placenta have been suggested as a possible source for regenerative medicine strategies based on isolated cell transplantation¹⁻³. We recently reported that hAECs have the ability to differentiate into hepatocytes in vitro and in vivo⁴ and were able to correct a mouse model of maple syrup urine disease⁵⁻⁶. Moreover, syngeneic rat-derived AECs differentiated into hepatocytes upon transplantation in the retrorsine (RS) model of liver repopulation, with no evidence of cell fusion⁷. Although hepatocytes are the main cell type in the liver, all other cell types have a role during the regeneration process. After partial hepatectomy, for example, together with the hepatocytes, hepatic sinusoidal endothelial cells (HSECs) and cholangiocytes, have to extensively proliferate in order to form the new vessels and sinusoids, and the bile ducts, respectively, thus reestablishing the functional structure of liver lobules⁸⁻⁹.

The possibility that AECs possess the ability to contribute to other cellular compartments of the liver has never been tested. The present study focuses on the differentiation of AECs into HSECs both in vitro and upon transplantation in an animal model of liver repopulation.

¹ Experimental Medicine Unit, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy
² Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
* Monica Serra and Michela Marongiu equally contributed to this work.

Submitted: October 11, 2016. Revised: June 20, 2017. Accepted: July 7, 2017.

Corresponding Author:
Fabio Marongiu, Experimental Medicine Unit, Department of Biomedical Sciences, University of Cagliari, Via Porcelli, 4-4 Piano, 09124 Cagliari, Italy. Email: fabiomarongiu@unica.it
Materials and Methods

Animals

All animals were maintained on daily cycles of alternating 12 h light/darkness with food and water available ad libitum. They were fed Purina Rodent Lab Chow diet throughout the experiment and received humane care according to the criteria outlined in the National Institutes of Health Publication 86-23, revised 1985. Animal studies were reviewed and approved by the University of Cagliari Ethical Committee for Animal Experimentation.

Isolation and Maintenance of rAECs, hAECs, and Human Umbilical Vein Endothelial Cells (HUVECs)

rAECs were isolated from the placentae of Fischer 344 wild type (dipeptidyl peptidase type IV, DPP-IV⁺) pregnant rats at 16–19 d of gestational age as previously described. A total of 20 placentae from 3 different pregnant rats were used. In order to avoid endothelial cell contamination, the yolk sac (YS) membrane (which is finely vascularized) was carefully peeled and only the inner white avascular membrane (amniotic membrane) was collected (Fig. 1, panels A–C). After a quick wash in phosphate buffered saline (PBS), amniotic membranes were digested in trypsin/ethylenediaminetetraacetic acid [EDTA] 0.05% (Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C for 20–30 min. The cell suspension was passed through a 100 μm strainer, centrifuged, and resuspended in PBS. Cell viability was assessed by Trypan blue dye exclusion and consistently exceeded 98%.

Human term placentae were collected from healthy women undergoing caesarean section after obtaining informed written consent. hAECs were isolated via trypsin/EDTA 0.05% digestion as previously described. Viability was >90%.

Both rAECs and hAECs were cultured under standard conditions in Dulbecco’s modified Eagle’s medium (DMEM) (high glucose) with 2 mM l-glutamine, 1% non-essential amino acids, 55 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 10% fetal bovine serum (FBS) (all from Thermo Fisher Scientific), and 10 ng/mL epidermal growth factor (EGF, Peprotech, Rocky Hill, NJ, USA).

At the same time as hAEC isolation, HUVECs were isolated from the umbilical cord as previously described and used as a positive control. HUVECs were maintained in Medium 200 supplemented with low-serum growth supplement (LSGS, Thermo Fisher Scientific).

Fig. 1. (A–C) Isolation of rat-derived amniotic epithelial cells (rAECs). Careful separation of avascular amniotic membrane (red arrow) from the finely vascularized yolk sac (black arrow) is necessary in order to avoid endothelial cell contamination. (D–I) Standard culture of AECs and in vitro tube formation assay (100× magnification). (D) rAEC standard culture conditions on plastic. (E and F) rAEC after 24 h tube formation assay. (G) hAEC standard culture conditions on plastic. (H and I) hAECs after 24 h tube formation assay.
Transplantation

Fischer 344 (DPP-IVnull) dipeptidyl peptidase type IV rats were used as recipients (n = 5). Four-week-old female rats were given 2 intraperitoneal injections of 30 mg/kg RS (Sigma-Aldrich, St. Louis, MO, USA), 2 wk apart. One month after RS treatment, recipient animals received 2/3 partial hepatectomy and *1.5/C2106 freshly isolated rAECs were injected via a mesenteric vein. Animals were killed at different time points up to 12 mo after cell transplant.

Endothelial Cell Tube Formation Assay

In order to promote capillary-like formation, a well-established angiogenesis assay was used. Briefly, 5 × 10⁴ rAECs, hAECs, and HUVECs were seeded on chamber slides previously coated with 100 μL of Geltrex (Thermo Fischer Scientific) per cm². Cells were cultured for 24 h in Medium 200 supplemented with LSGS.

Histochemical and Immunofluorescence Analyses

To follow the fate of transplanted cells, histochemical detection of DPP-IV positive clusters was performed on 5 μm frozen sections as previously described. Double immunofluorescence staining of DPP-IV (hereafter referred as CD26) and SE-1, RECA-1, cytochrome P450 (CYP) 2E1, 3A1, or hepatocyte nuclear factor 4α (HNF4α) was performed on 5 μm thick frozen sections as follows: briefly, slides were fixed in cold acetone for 10 min, then blocked with 4% paraformaldehyde (PFA) for 10 min. Cells were permeabilized and epitopes exposed by incubating with 0.1% triton for 30 min. After blocking with goat serum, slides were incubated with anti-CD26 antibody for 2 h at RT. After washing, cells were incubated with secondary anti-rabbit Dylight 488-conjugated antibody for 1 h at RT. Nuclei were counterstained with DAPI.

All slides were examined with an IX71 fluorescence microscope (Olympus, Tokyo, Japan). For a complete list of antibodies, see Table 1.

Transmission Electromicroscopy (TEM)

Differentiated hAECs were fixed with 2% glutaraldehyde containing 5–10 M verapamil, 5–10 M EDTA, adjusted to pH 7.4, and then postfixed with aqueous 1% osmium tetroxide. The fixed samples were dehydrated and embedded with epon. The 50 nm ultrathin sections were cut and stained with 2% uranyl acetate and lead. TEM analysis was performed using a JEOL 1210 TEM system (JEOL USA, Peabody, MA, USA).

Results

Rat- and Human-derived AECs Form Capillary-like Structures In Vitro

rAECs were isolated by carefully separating the avascular amniotic membrane from the finely vascularized YS (Fig. 1, panels A–C). When cultured on a plastic substrate with standard culture medium, rAECs promptly adhered to the plate and formed a monolayer of cells with homogeneous morphology (Fig. 1, panel D; panel G shows hAECs for comparison). In order to evaluate the ability of both rAECs and hAECs to respond to angiogenic signals, a well-established in vitro assay for endothelial cell tube formation was used. After 24 h in culture on Geltrex substrate with a proangiogenic medium, both rat and human cells arranged into a capillary-like network of cells (Fig. 1, panels E, F, H, and Table 1. List of Antibodies.

| Epitope                   | Host/Type       | Dilution | Brand/Cat. No.            |
|---------------------------|-----------------|----------|---------------------------|
| CD31/PECAM-1              | Rabbit polyclonal | 1:100    | Novus Biologicals (Littleton, CO, USA) NB100-2284 |
| CD26                      | Mouse monoclonal | 1:150    | BD Pharmingen (San Jose, CA, USA) 559639    |
| RECA-1                    | Mouse monoclonal | 1:50     | Abcam (Cambridge, United Kingdom) ab9774    |
| SE-1                      | Mouse monoclonal | 1:500    | Novus Biologicals NB110-68095    |
| CYP 3A1                   | Rabbit polyclonal | 1:500    | Abcam ab22733    |
| CYP 2E1                   | Rabbit polyclonal | 1:250    | Abcam ab28146 |
| Hepatocyte nuclear factor 4α | Mouse polyclonal | 1:100    | Abcam ab41898 |
| Anti-Mouse Dylight 488 conj. | Goat polyclonal | 1:250    | Abcam ab96879    |
| Anti-Rabbit Dylight 488 conj. | Goat polyclonal | 1:250    | Abcam ab96899    |
| Anti-Mouse Atto 550 conj. | Goat polyclonal | 1:250    | Sigma (St. Louis, MO, USA) 43394    |

Serra et al.
and 1). However, rAECs showed a lower capacity to form tubes, which were mostly 1-cell thick (Fig. 1, panels E and F) as compared to hAECs, where thickness ranged from 1 to several cells (Fig. 1, panels H and I). Moreover, the analysis of the ultrastructure of hAEC-derived tubes revealed the presence of a rudimentary lumen (Fig. 2). The expression of endothelial cell marker CD31/platelet endothelial cell adhesion molecule (PECAM-1) was also evaluated on AEC-derived web structures. Both hAECs (Fig. 3, panels A–C) and rAECs (Fig. 3, panels D–F) expressed CD31 in the cytoplasm and at lower levels as compared to controls (HUVECs and rat small vein, Fig. 3, panels G–L), where the expression was mainly localized on the cell membrane. Control samples cultured on plastic did not express the endothelial cell marker (Fig. 3, panels M–P).

**Donor-derived Clusters Have Morphology and Pattern of Expression of CD26 Typical of HSECs**

Upon transplantation of rAECs into a rat model for liver repopulation, clusters of donor-derived cells were identified by histochemical detection of CD26 into the liver of recipient animals. As shown in previous studies4,7 and in Fig. 4, panel A, rAECs were able to engraft and differentiate into hepatocytes upon transplantation into the liver of female rats previously treated with 2 doses of 60 mg/kg of RS. As expected, the expression pattern of CD26 in rAEC-derived hepatocytes was polarized and localized at the bile canaliculi between two hepatocytes15. However, when females rats were treated with 2 doses of 30 mg/kg of RS, rAEC-derived clusters consistently showed a different morphology, in which the cells were engrafted in between resident hepatocytes and resembled HSECs as CD26 expression was homogeneously distributed in the cytoplasm (Fig. 4 panel B).

**rAEC-derived Cells Express Markers of HSECs**

To confirm the endothelial nature of donor-derived cells, immunofluorescence staining of endothelial markers RECA-1 and SE-1 was performed on serial sections. In all the observed clusters that showed HSEC morphology, CD26 positive cells also expressed RECA-1 (Fig. 4, panels C–E) and SE-1 (Fig. 4, panels F–H).

**rAEC-derived Cells Do Not Express Mature Hepatocyte Markers**

In order to rule out the possibility that donor-derived cells had an intermediate phenotype, immunofluorescence staining for mature hepatocyte markers CYP 3A1, 2E1, and hepatocyte nuclear factor 4α (HNF4α) was performed on serial sections. In all the observed clusters, no colocalization of CD26 with hepatocyte markers was identified, thus confirming the endothelial nature of donor-derived cells (Fig. 5).

**Discussion**

In a recent study, Vácz et al. reported transient engraftment of hAECs into the carotid artery of experimental animals after balloon injury without immunosuppressive treatment, although no improvement in vascular function was observed16.

In the present study, we explored the possibility that epithelial cells isolated from the amniotic membrane differentiate into endothelial cells both in vitro and in an animal model of liver repopulation. For the purposes of this study, and considering that placenta is a highly vascularized tissue, it was important to exclude the possible presence of endothelial cells in the rAEC preparation. In mice and rats, the amnion is flanked by the visceral YS17. While the amniotic membrane is thin and avascular, YS is thicker and finely vascularized (Fig. 1, panels A–C). In order to avoid possible endothelial cell contamination, at the time of amnion dissection, YS was carefully removed.

In a first set of experiments, we evaluated the ability of rAECs and hAECs to respond to proangiogenic signals utilizing a well-established protocol for in vitro endothelial cell tube formation13. This assay models the reorganization stage of angiogenesis and is commonly used with putative endothelial cells. When cultured under the appropriate experimental conditions, both rAECs and hAECs reorganized themselves into a network of cells within 24 h. Although rAECs formed fewer and thinner tubular structures as compared to hAECs, it is important to note that the stimuli administered in this assay are optimized for the culture of human rather than rat cells. This suggests that AECs from human and rat origin possess a similar ability to respond to angiogenic signals, although an optimized protocol might be needed for rAECs to respond to the same extent as hAECs.
Interestingly, hAEC-derived capillary-like structures were mainly composed of >1 cells, and when analyzed at the ultrastructural levels, they revealed the presence of a rudimentary lumen. Both rAEC- and hAEC-derived tubular structures were positive for the expression of CD31/PECAM-1. However, the localization of this molecule, which is normally expressed at the membrane, was mainly cytoplasmic. This suggests that, although AECs possess the ability to respond to angiogenic signals, they do not express a fully mature endothelial phenotype in vitro.

Fig. 3. Immunofluorescence analysis of CD31 expression. (A–C) Human-derived amniotic epithelial cell (hAEC)–derived capillary structures. (D–F) Rat-derived amniotic epithelial cell (rAEC)–derived capillary structures. (G–I) Human umbilical vein endothelial cell–derived capillary structures (human positive antibody control). (J–L) Rat small vein (rat positive antibody control). (M and N) hAECs cultured on plastic, 24 h postisolation. (O and P) rAEcs cultured on plastic, 24 h postisolation. (Q and R) Human negative antibody control (no primary antibody). (S and T) Rat negative antibody control (no primary antibody). 100× Magnification. Insets show 200× magnification.
To test the differentiation of rAECs into endothelial cells in vivo, the RS model of liver repopulation was used. RS is a naturally occurring molecule that is known for its ability to impose a persistent block in the cell cycle of the hepatocytes of treated animals, through the induction of a senescent phenotype\(^\text{18–20}\). This allows for the growth of transplanted healthy hepatocytes that have the ability to fully repopulate the liver by replacing the impaired resident cells. However, the effect of pyrrolizidine alkaloids (PAs), including RS, is also targeted to endothelial cells\(^\text{21}\). For example, monocrotaline, a related PA, is able to induce pulmonary hypertension in experimental animals because of its targeted effect on lung endothelial cells\(^\text{22,23}\).

In the present study, undifferentiated rAECs were isolated from F344 pregnant rats and transplanted into the liver of syngeneic female RS-treated animals. As previously described, when recipients were treated with 2 doses of 60 mg/kg of RSA, rAECs engrafted and formed discrete clusters of mature hepatocytes\(^\text{4,7}\). However, when the RS dose was reduced to 30 mg/kg, all donor-derived clusters showed

---

**Fig. 4.** (A and B) Histochemical detection of DPP-IV (CD26) positive donor-derived clusters into the liver of recipient animals. (A) Cluster of engrafted rAECs after differentiating into hepatocytes: the expression pattern of CD26 in rAEC-derived cells is polarized and localized at the bile canaliculi between 2 hepatocytes (see inset). (B) rAEC-derived clusters with morphology of hepatic sinusoidal endothelial cells: cells were engrafted in between resident hepatocytes and CD26 expression was homogeneously distributed in the cytoplasm (see inset). (C–H) Double immunofluorescence staining for CD26 and endothelial markers RECA-1 and SE-1 performed on serial liver tissue sections. In all the observed clusters, CD26 positive cells also expressed RECA-1 and SE-1. (C–E) RECA-1 + CD26 staining; (F–H) SE-1 + CD26 staining. 200× Magnification. Insets show 600× magnification.
a peculiar morphology and a pattern of expression of CD26 that resembled that of HSECs. This suggests that, at lower doses, RS has a more selective toxicity against the endothelium, although further studies are needed to characterize the effects of this molecule on the female rat. Most importantly, clusters of donor-derived cells were stably engrafted into the recipient liver up to 12 months post-transplant (or after transplant). Immunofluorescence analysis of CD26-positive clusters revealed that donor-derived cells expressed RECA-1, a marker specific for the vascular endothelium. Furthermore, they were positive for SE-1, an epitope specifically expressed by HSECs but not extrahepatic vascular endothelial cells. These findings confirmed that transplanted rAECs had differentiated into HSECs but not extrahepatic vascular endothelial cells. These findings confirmed that transplanted rAECs had differentiated into HSECs. In order to rule out the possibility that, upon transplantation, rAECs acquired an intermediate phenotype, tissue sections were stained with mature hepatocyte markers CYP 3A1, 2E1, and HNF 4α. No signs of colocalization of the above hepatocyte markers with CD26 antigen were discerned, further supporting the conclusion that rAECs fully differentiated into HSECs.

These results represent the first direct evidence that AECs respond to angiogenic signals in vitro and can stably engraft and differentiate into HSECs in vivo. Such findings add to our previous results supporting the conclusion that AECs possess great plasticity. Their ability to differentiate toward the endothelial lineage, particularly in an in vivo setting, makes them an attractive resource for regenerative medicine applications in the liver and possibly other organs.

**Acknowledgments**

We thank Dr. Franca Marongiu and Dr. Cristian Caria for their valuable scientific support. We also thank A. Saba and R. Marras for their excellent technical and secretarial assistance.

**Author Contribution**

Monica Serra and Michela Marongiu equally contributed to this work.

**Ethical Approval**

Animal studies were reviewed and approved by the University of Cagliari Ethical Committee for Animal Experimentation.

**Statement of Human and Animal Rights**

All animals received humane care according to the criteria outlined in the National Institutes of Health Publication 86–23, revised 1985.
Statement of Informed Consent

Human placentae were collected after obtaining informed written consent.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Sardinian Regional Government (RAS).

References

1. Strom SC, Skvorak K, Gramignoli R, Marongiu F, Miki T. Translation of amnion stem cells to the clinic. Stem Cells Dev. 2013;22(Suppl 1):96–102.
2. Miki T, Lehmann T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. Stem Cells. 2005;23(10):1549–1559.
3. Fanti M, Gramignoli R, Serra M, Cadoni E, Strom SC, Marongiu F. Differentiation of amniotic epithelial cells into various liver cell types and potential therapeutic applications. Placenta. 2017 Mar 30. pii: S0143-4004(17)30220-5. doi: 10.1016/j.placenta.2017.03.020. [Epub ahead of print].
4. Marongiu F, Gramignoli R, Dorko K, Miki T, Ranade AR, Paola Serra M, Doratiotto S, Sini M, Sharma S, Mitamura K, et al. Hepatic differentiation of amniotic epithelial cells. Hepatology. 2011;53(2):719–729.
5. Skvorak KJ, Dorko K, Marongiu F, Tahan V, Hansel MC, Gramignoli R, Arning E, Bottiglieri T, Gibson KM, Strom SC. Improved amino acid, bioenergetic metabolite and neurotransmitter profiles following human amnion epithelial cell transplant in intermediate maple syrup urine disease mice. Mol Genet Metab. 2013;109(2):132–138.
6. Skvorak KJ, Dorko K, Marongiu F, Tahan V, Hansel MC, Gramignoli R, Gibson KM, Strom SC. Placental stem cell correction of murine intermediate maple syrup urine disease. Hepatology. 2013;57(3):1017–1023.
7. Marongiu M, Serra MP, Contini A, Sini M, Strom SC, Laconi E, Marongiu F. Rat-derived amniotic epithelial cells differentiate into mature hepatocytes in vivo with no evidence of cell fusion. Stem Cells Dev. 2015;24(12):1429–1435.
8. Marrone G, Shah VH, Gracia-Sancho J. Sinusoidal communication in liver fibrosis and regeneration. J Hepatol. 2016;65(3):608–617.
9. Michalopoulos GK. Principles of liver regeneration and growth homeostasis. Compr Physiol. 2013;3(1):485–513.
10. Nakajima T, Enosawa S, Mitani T, Li XK, Suzuki S, Amemiya H, Koiwai O, Sakuragawa N. Cytological examination of rat amniotic epithelial cells and cell transplantation to the liver. Cell Transplant. 2001;10(4-5):423–427.
11. Miki T, Marongiu F, Dorko K, Ellis EC, Strom SC: Isolation of amniotic epithelial stem cellsCurr Protoc Stem Cell Biol. 2010; Chapter 1. Unit 1E.3.
12. Baudin B, Brunel A, Bosselut N, Vaubois-Molle M. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protoc. 2007;2(3):481–485.
13. Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human ‘angiogenesis’ assays with capillaries formed in vivo. Angiogenesis. 2001;4(2):113–121.
14. Thompson NL, Hixon DC, Callanan H, Panzica M, Flanagan D, Faris RA, Hong WJ, Hartel-Schend S, Doyle D, A Fischer rat strain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model. Biochem J. 1991;273(Pt 3):497–502.
15. Stecca BA, Nardo B, Chieco P, Mazzotti A, Bolondi L, Cavalieri A. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. J Hepatol. 1997;27(3):337–345.
16. Vázquez R, Cseleényák A, Cserép Z, Benkő R, Kovács E, Pankotai E, Lindenmair A, Wolbair S, Schwarz CM, Horváthy DB, et al. Effects of amniotic epithelial cell transplantation in endothelial injury. Inter Med Appl Sci. 2016;8(4):164–171.
17. Dobrev MP, Pereira PNG, Deprest J, Zwijsen A. On the origin of amniotic stem cells: of mice and men. Int J Dev Biol. 2010;54(5):761–777.
18. Laconi E, Oren R, Mukhopadhyay DK, Hurston E, Laconi S, Pani P, Dabeva MD, Shafritz DA. Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retorsine. Am J Pathol. 1998;153(1):319–329.
19. Laconi E, Pilar S, Porcu PP, Shafritz DA, Pani P, Laconi E. Massive liver replacement by transplanted hepatocytes in the absence of exogenous growth stimuli in rats treated with retorsine. Am J Pathol. 2001;158(2):771–777.
20. Serra MP, Marongiu F, Sini M, Laconi E. Hepatocyte senescence in vivo following preconditioning for liver repopulation. Hepatology. 2012;56(5):760–768.
21. Edgar JA, Molyneux RJ, Colegate SM. Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol. 2015;28(1):4–20.
22. Nogueira-Ferreira R, Vitorino R, Ferreira R, Henriques-Coelho T. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015;35:8–16.
23. Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992;22(5–6):307–325.